« Return to News | Drug Sponsors

Sigma-Aldrich acquires Research Organics

Wednesday, April 4, 2012 10:53 AM

Sigma-Aldrich, a life science and high technology company, has acquired all outstanding shares of Cleveland-based Research Organics, a supplier of high purity biochemicals.

The acquisition will expand Sigma-Aldrich’s buffer production capacity and increase its portfolio of PharmaGrade raw materials for the biopharmaceutical and diagnostic markets. Research Organics will transition into SAFC, the custom manufacturing and services business unit of Sigma-Aldrich. 

"This acquisition is an outstanding complement to our existing raw materials portfolio and will help us provide more innovative solutions for some of our customers' toughest supply challenges,” said Gilles Cottier, executive vice president of Sigma-Aldrich and president of SAFC. “It will also enable us to provide SAFC's customers with true dual sourcing of buffers from two of the world's leading manufacturing sites." 

Founded in the 1950's, Research Organics was a pioneer in manufacturing zwitterionic biological buffers and developing the HEPES buffer as an industry-standard. 

Rob Sternfeld, president of Research Organics, said, "The acquisition provides the resources to expand the growth of our business, to enhance our product line and to upgrade our facilities to meet ever changing industry requirements.”

Terms of the purchase were not disclosed. Sigma-Aldrich expects the acquisition to be neutral to earnings per share in 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.